Kornimate/medical-research-clean huggingface dataset:
excitotoxicity markers and the clinical-radiological progression after a demyelinating event: a prospective pilot study

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is an inflammatory disease of the central nervous system, beginning most often in subjects aged 20-40 years. in france, thanks to recent studies reported during general states of ms in 2006, the prevalence is estimated at 65.5 / 100,000 population (96.3 / 100,000 women and 41.9 / 100,000 men) and incidence at 7.91 per 100,000. in lower normandy, the incidence of ms is estimated to 4.45 / 100,000 inhabitants or 60 new cases per year. the primary objective of this pilot study is to assess the levels of glutamate and aspartate (excitotoxicity markers) and their repercussions on the clinical and radiological outcome in 40 patients experiencing an event demyelinating central nervous system.


Eligibility criteria:
inclusion criteria: * man or woman between 18 and 60 years old. * patient with one or more type of inflammatory events of central system suggestive of demyelinating disease (multiple sclerosis, neuromyelitis optical devic extensive myelitis) * no treatment with corticosteroids for less than 1 month * need for a lumbar puncture performed in the etiologic * need a brain mri performed within the etiologic * patient who signed informed consent exclusion criteria: * secondary progressive ms * any cons-indication for lumbar puncture * any contra-indication to mri * minor patient or patient major under guardianship
study the effect of oral zinc supplementation on high molecular weight zinc binding protein in semen

Conditions: Asthenozoospermia

Summary: there are several causes leading to male infertility, like oxidative stress, and nutritional deficiency of trace elements like zinc. zinc in human seminal plasma was divided into three types of ligands which are high (hmw), intermediate (imw), and low molecular weight ligands (lmw). the present study was conducted to study the effect of zn supplementation on the quantitative and qualitative characteristics of semen along with zinc binding protein levels in semen of patients with asthenozoospmia.

elevation of ros levels lead to an increase the oxidation of hmw-zn binding proteins in seminal plasma of asthenozoospermic subjects. zinc supplementation restores hmw-zn% in seminal plasma of asthenozoospermic subjects to normal value. lmw-zn% is elevated in seminal plasma of asthenozoospermic patients. it may be because increment the levels of semenogelin in seminal plasma of asthenozoospermic subjects. zinc supplementation elevates lmw-zn% in seminal plasma of asthenozoospermic subjects to more than normal value, this may be because of its enhancement of the synthesis of metallothioneins (low molecular weight zinc binding protein).

Eligibility criteria:
inclusion criteria: the inclusion criteria were the presence of asthenozoospermia in the semen sample. exclusion criteria: * the absence of endocrinopathy, * varicocele, and * female factor infertility. smokers and alcoholic men were excluded from the study because of their recognized high seminal ros levels and decreased antioxidant levels.

Keywords: zinc binding protein
autologous bone marrow stem cell transplantation in patients with spinal cord injury

Conditions: Spinal Cord Injury

Summary: this research investigates the use of autologous bone marrow stem cells in patients with spinal cord injury.

the aim of this study is to evaluate autologous bone marrow stem cells transplantation as a safe and potentially beneficial treatment for patients with spinal cord injury.

Eligibility criteria:
inclusion criteria: * age between 18 and 50 years old * traumatic spinal cord injury at the thoracic or lumbar level * classification frankel a * indication for spinal surgery for traumatic lesions of bone exclusion criteria: * section of the spinal anatomy * open injuries * active infectious diseases * terminal patients * neurodegenerative diseases * primary hematologic diseases * bone reflecting increased risk for spinal puncture * coagulopathies * hepatic dysfunction * pregnancy * other medical complications that contraindicate surgery, including major respiratory complications * participation in another clinical trial * use of metal implants close to vascular structures (such as cardiac pacemaker or prosthesis) that contraindicate mri

Keywords: spinal cord injury mesenchymal stem cells bone marrow
long-term follow-up study of rgx-314 administered in the suprachoroidal space for participants with namd

Conditions: Neovascular Age-Related Macular Degeneration (nAMD); Gene Therapy; AMD; Wet AMD; wAMD; nAMD

Summary: this is a prospective, observational study designed to evaluate the long-term safety and efficacy of rgx-314. eligible participants are those who were previously enrolled in a clinical study of namd in which they received suprachoroidal space (scs) administration of rgx-314. enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. participants will be followed for up to 5 years after rgx-314 administration (inclusive of the parent study). as such, the total study duration for each participant may vary depending on when they enroll in the current study following rgx-314 administration in the parent study.


Eligibility criteria:
inclusion criteria: 1. must provide written, signed informed consent for this study. 2. must have been enrolled in a previous clinical study of rgx-314 in the treatment of namd and must have received an scs injection of rgx-314 in that study. 3. must be willing and able to comply with all study procedures. exclusion criteria: 1. none
acamprosate in the treatment of pathological gambling

Conditions: Pathological Gambling

Summary: the purpose of this study is to see whether acamprosate (campral) will curb the desire to gamble in people with pathological gambling disorder.

because the opiate antagonists appear to be effective in the treatment of pathological gambling (pg), it is reasonable to ask whether acamprosate (calcium acetylhomotaurine; campral), also fda approved for the treatment of alcoholism, can be used effectively to treat pg. acamprosate is not an opioid antagonist; rather, it is assumed that its therapeutic effects are due to actions on gaba receptors. acamprosate is structurally related to 1-glutamic, which is an excitatory neurotransmitter. it has been proposed that acamprosate decreases the effects of the naturally-occuring excitatory neurotransmitter glutamate in the body. because chronic alcohol consumption disrupts this system, and the changes last many months after alcohol ingestion is stopped, it is possible that acamprosate restores the glutamate system towards normal. regardless, acamprosate decreases the pleasant "high" associated with alcohol consumption, and thus decreases the frequency of relapse during abstinence. we hypothesize that acamprosate will have similar actions in persons with pg.

Eligibility criteria:
inclusion criteria: * patients will meet dsm-iv (diagnostic and statistical manual 4th edition) criteria for pathological gambling disorder * patients will achieve a sogs (south oaks gambling screen) score greater than or equal to 5 * patients will be 18 years old or older * patients will speak standard english * patients will be able to give written informed consent * patients will be able to understand and cooperate with study procedures exclusion criteria: * patients having a current (past 3 months) substance use disorder (except dependence) * patients having a hamilton depression rating score of greater than or equal to 18 or a score on #1 (depressed mood) greater than 1. * patients having a clinically significant medical illness * patients at risk for aggressive or suicidal behavior * patients who have received the following interventions within the proscribed time prior to study entry: 1) a monoamine oxidase inhibitor within the previous 21 days; 2) long-acting phenothiazines within the previous 3 months; 3) other psychotropic drugs within the previous 14 days; 4) flu- oxetine within the previous 4 weeks. * patients having severe antisocial or borderline personality disorder * patients with a past or current diagnosis of schizophrenia, schizoaffective disorder, psychotic disorder, bipolar disorder, or delirium, dementia, or other clinically significant cognitive disorder. * patients initiating individual, group, or couple psychotherapy during the three moths prior to study entry (excluding gambler's anonymous) * patients having prior exposure to acamprosate

Keywords: acamprosate, impulse-control disorders
managing inflammatory bowel disease

Conditions: Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis

Summary: inflammatory bowel disease (crohn's disease and ulcerative colitis) often results in significant life disruption, hospitalization and surgery. while psychosocial factors are not believed to cause ibd, such factors can contribute to the ability of individuals with ibd to cope with the disease, and ineffective coping may lead to the exacerbation of ibd symptoms. the goal of this study is to evaluate the efficacy of a social learning and cognitive behavior therapy approach for treating children with ibd. the primary outcomes of interest are ibd symptoms, medical visits, quality of life, and overall disability.

inflammatory bowel disease (crohn's and ulcerative colitis; ibd), a serious medical condition that affects children and adolescents, is often associated with high rates of health care utilization and disability, including school absences. while psychosocial factors are not believed to cause ibd, research suggests that they may increase illness-related dysfunction. prior studies suggest that response to chronic illness is, in part, acquired during childhood through social learning processes and may be modified with psychosocial interventions. this randomized controlled trial will compare a social learning and cognitive behavior therapy (slcbt) treatment to an education and support condition (es). 180 children with ibd will be recruited and followed for 12 months. it is hypothesized that slcbt participants, compared to those in the es condition, will, at one-year follow-up: 1) exhibit greater decreases in ibd symptoms, medical visits for ibd, and functional disability, and greater increases in quality of life; 2) demonstrate greater use of cognitive coping, relaxation and stress management skills, and their parents will demonstrate greater reductions in maladaptive responses to illness behavior; and 3) exhibit greater reductions in anxiety, depression, and somatization. results will lead to innovative interventions for ibd and other chronic childhood medical conditions.

Eligibility criteria:
inclusion criteria: * child has been diagnosed for at least 3 months * child age is 8-17 * child has lived with primary caregiver full-time for at least the past 5 years and for at least half of his/ her lifetime * child is medically approved to engage in normal daily activities exclusion criteria: * chronic disease other than ibd (e.g., pancreatitis, diabetes, epilepsy) * major surgery in past year unrelated to ibd * developmental disabilities that require full-time special education or that impair ability to respond to treatment

Keywords: crohn's disease ulcerative colitis inflammatory bowel disease illness behavior cognitive behavioral therapy
effectiveness and adherence of modified alternate-day calorie restriction (macr) in non-alcoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: there is no effective therapy for non-alcoholic fatty liver disease (nafld), although intensive calorie restriction is typically recommended but dietary adherence is an issue. currently, there are no studies had been focusing the effect of modified alternate day calorie restriction in nafld patient focusing on changes in liver steatosis and fibrosis.

disease activity and progression of non-alcoholic fatty liver disease (nafld) to non-alcoholic steatohepatitis (nash) and cirrhosis can be highly variable, where 2-3% will eventually progress to end-stage liver diseases. with the rising prevalence of metabolic syndrome and obesity, nafld has become the most frequent form of chronic liver disease in the west but also in asia. there are good evidence that weight loss is effective in improving liver histology in nafld, for example, 31 obese patients with nash was randomised into intensive lifestyle changes over 48 weeks versus structured basic education only, and the intensive lifestyle group showed significant improvements in steatosis, necrosis, and inflammation. intense calorie restriction is the recommended form of dietary strategy for management of nafld. even though such intense dietary strategy has proven to be effective, some patients find it difficult to adhere and maintain. on the other hand, intermittent fasting achieves more consistent weight loss by improving adherence, as intermittent fasting only requires calorie restriction every other day compared to conventional form of daily calorie restriction. alternate day calorie restriction can be divided into two components, a 'feed day' and a 'fast day' where food is consumed ad libitum for 24 hours period alternating with either complete or partial (modified) calorie restriction for the next 24 hours. macr, the dietary strategy employed in the investigator's study, restricts 70% of an individual's daily requirement of calorie per day. there are other forms of intermittent fasting, for example, 2-4 days of ad libitum feeding alternating with 2-4 days of calorie restriction. currently, there are no approved pharmacological therapies for nafld, and many guidelines advocate recommendation with a focus on controlling risk factors and lifestyle interventions that include dietary and physical activities. no specific nafld trials have evaluated the effectiveness of modified form of intermittent fasting in the control of nafld activity.

Eligibility criteria:
inclusion criteria: * have elevated alt or ast level (alt \>41 or ast\>34 iu/l) * no evidence of other forms of liver diseases * for those with diabetes mellitus and dyslipidaemia, they must be on a stable therapy for at least 6 months prior to study enrolment exclusion criteria: * significant alcohol consumption (\> 1 standard drink per day) * pregnancy * involvement in an active weight loss program or taking weight loss medications * substance abuse and significant psychiatric problems.

Keywords: non-alcoholic fatty liver disease
shock wave lithotripsy using fluoroscopic versus ultrasonic localization

Conditions: Stone, Kidney; Child, Only

Summary: epidemiological studies have shown a progressive increase in the incidence of pediatric urolithiasis over the past few decades.

pediatric stone disease is considered endemic in developing nations including turkey, pakistan, and eastern countries. the introduction of swl by chaussy et al. in the early 1980s revolutionized the management of upper urinary tract calculus disease. reports of successful swl in children were first published in 1986; then several reports showed safety, and stone-free rates comparable with those of adults. for successful swl, accurate localization of the shock waves is performed by ultrasound (us) or fluoroscope (fs) to fully focus the shock waves on the stone

Eligibility criteria:
inclusion criteria: * children (2-16) years of age with radiopaque renal pelvic stones less than 20 mm exclusion criteria: 1. previous percutaneous nephrolithotripsy at the same side. 2. previous renal exploration for stones at the same side. 3. positive urinary culture. 4. calyceal stones

Keywords: pediatric renal stones ultrasound shock waves fluoroscope.
neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage ⅱ b and iiia squamous cell carcinoma of the lung

Conditions: Non-small Cell Lung Cancer

Summary: albumin-bound paclitaxel plus carboplatin regimen in advanced nsclc especially in lung squamous cell carcinoma has a better tumor response rate and safety, therefore.the main purpose of this study is to observe the safety and efficacy of albumin-bound paclitaxel / carboplatin in the treatment of lung squamous cell carcinoma of stage iib and iiia.

albumin-bound paclitaxel plus carboplatin regimen in advanced nsclc especially in lung squamous cell carcinoma has a better tumor response rate and safety, therefore, this program is applied to neoadjuvant therapy, may obtain better tumor pathological remission rate, improve the operation resection rate, thus improve the prognosis.the main purpose of this study is to observe the safety and efficacy of albumin-bound paclitaxel / carboplatin in the treatment of lung squamous cell carcinoma of stage iib and iiia.

Eligibility criteria:
inclusion criteria: 1.histological or cytological diagnosis of lung squamous cell carcinoma of stage iib and iiia. 2.18 years or older 3.ecog performance status no more than 2; 4.appraisable disease, the presence of at least three lesions if longest diameter \<10 mm by brain mri; 5.haemoglobin 10.0 g/dl, absolute neutrophil count (anc) 1.5 x 10e9/l, platelets 100 x 10e9/l; 6.total bilirubin 1.5 x upper limit of normal (uln); 7.alt and ast \< 2.5 x uln in the absence of liver metastases, or \< 5 x uln in case of liver metastases; 8.creatinine clearance 60ml/min (calculated according to cockcroft-gault formula). exclusion criteria: 1. any systemic anticancer treatment for nsclc 2. local radiotherapy for nsclc. 3. in this study within five years prior to the start of treatment with other than nsclc patients with other cancers. 4. any instability in systemic disease, including: active infection, absence of control hypertension, unstable angina, begins in the last 3 months of angina pectoris, congestive heart failure 5. hiv infection; 6. allergic to paclitaxel or platinum; 7. mixed with adenocarcinoma, small cell lung cancer; 8. pregnant or lactating women; 9. other researchers believe that does not fit into the group

Keywords: squamous cell carcinoma of the lung
work productivity in active ankylosing spondylitis (as) patients treated with enbrel.

Conditions: Ankylosing Spondylitis

Summary: patients with ankylosing spondylitis more frequently discontinue work. this study measures the impact of enbrel on work participation.

purely descriptive

Eligibility criteria:
inclusion criteria: * active as patients (as judged by the treating md) who are currently employed. * patients who are scheduled by their rheumatologist to initiate treatment with etanercept. exclusion criteria: * patients who initiated a procedure for eligibility of work disability/pension. * patients with previous use of tnf-alpha inhibitors either in commercial use, or in a study for the treatment of as or a related spondylarthropathy condition.
buprenorphine maintenance for opioid addicts - 2

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to evaluate varying doses of buprenorphine for opioid dependence and cocaine abuse.


Eligibility criteria:
please contact site for information.

Keywords: opioid-related disorders
parkinson's kinetigraph, pkg in patients with deep brain stimulation and continuous levodopa infusion therapy

Conditions: Parkinson's Disease

Summary: in this study the aim is to evaluate the outcome of deep brain stimulation (dbs) and continuous intraduodenal levodopa therapy in patients with advanced parkinson' disease by using parkinson's kinetigraph™ device which is a movement and acceleration measuring device. in this study we also evaluate the usability of parkinson's kinetigraph™ device by comparing it with written patient diaries.

in this study the aim is to evaluate the outcome of deep brain stimulation (dbs) and continuous intraduodenal levodopa therapy in patients with advanced parkinson' disease by using parkinson's kinetigraph™ logger (pkg) device which is a movement and acceleration measuring device. a measurement is done before and after the implantation of selected therapy. pkg will measure automatically in every two minutes the movement of selected limb (usually the more affected upper extremity) for six days. at the same time a patient will keep a written diary of his/her parkinsonian symptoms. diary and collected pkg data will be compared. pkg will also remind with vibration the patient of the time drug administration and the patient can confirm this with pressing a button on pkg. the collected data will be transmitted to a computer and analyzed mathematically to produce a visual graph of daily movements. the aim is to evaluate pkg's usability in measuring parkinsonian symptoms and in evaluation the outcome of dbs and levodopa therapy. main parameters in evaluation are bradykinesia score and dyskinesia score.

Eligibility criteria:
inclusion criteria: * patient with diagnosed parkinson's disease * parkinson's disease is in advanced state (defined by the treating physician) * a good response with over 30 % improvement of scores in unified parkinson's disease rating scale part iii in pre-dbs evaluation exclusion criteria: * age older than 70 years (this is a clinical exclusion criteria for dbs treatment) * no history of psychosis or depression (this is a clinical exclusion criteria for dbs and intraduodenal levodopa therapy) * no diagnosed dementia (this is a clinical exclusion criteria for dbs and intraduodenal levodopa therapy)